Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
Status:
Terminated
Trial end date:
2013-04-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the best dose, safety and side effects of
ridaforolimus when given with cetuximab for patients with head and neck, lung and colon
cancer that has progressed after initial therapy. A second purpose of this study is to gain
preliminary information on whether the combination of ridaforolimus and cetuximab is helpful
in treating patients with advanced head and neck cancer
Phase:
Phase 1
Details
Lead Sponsor:
Angela Taber MD
Collaborators:
Memorial Hospital of Rhode Island Rhode Island Hospital Roger Williams Medical Center The Miriam Hospital